November 2025A pan-tumor and pan-country approach to LLM-based extraction of systemic therapies from the electronic health recordTumor agnosticArtificial intelligenceData Quality
May 2023Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer typesTumor agnosticClinical development
May 2021Statistical methods for pantumor analysis: models to account for tumor-level heterogeneityMethodologyTumor agnostic
April 2021TRK fusion cancer: patient characteristics and survival analysis in the real-world settingTumor agnosticClinical development
October 2020What can real-world data tell us about the prognostic significance of an emerging biomarker?Tumor agnosticReal-World DataClinical development
May 2020Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approvalTumor agnosticRegulatoryReal-World DataTreatment and Testing patterns
January 2020Cancers with NTRK gene fusions: molecular characteristics and prognosisTumor agnosticClinical development
September 2019Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world datasetTumor agnosticClinical development
September 2019Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patientsTumor agnosticClinical development